Aurobindo Pharma arm incorporates new subsidiary in US
Hyderabad: Aurobindo Pharma Limited has announced the incorporation of a new wholly owned subsidiary in the United States through its arm Aurobindo Pharma USA Inc. The newly formed entity, CRESEDEMO PHARMA LLC, was incorporated on June 13, 2025, with the aim of expanding the company’s pharmaceutical products business in the US market.
According to a regulatory filing, CRESEDEMO PHARMA LLC will function within the pharmaceutical sector.
The new entity has been formed with an initial capital infusion of USD 10,000, divided into 10,000 shares at USD 1 each. The entire subscription has been made in cash.
No regulatory approvals were needed for the establishment of the new entity.
In May 2025, Curateq Biologics Private Limited, a wholly owned subsidiary of the Company, incorporated a new wholly owned subsidiary in the Netherlands by the name of CuraTeQ Biologics B.V.
Further strengthening its domestic capabilities, in October 2024, Lyfius Pharma, a wholly owned step-down subsidiary of Aurobindo Pharma, inaugurated its state-of-the-art PenG manufacturing facility, at Kakinada, Andhra Pradesh.
Read also: Aurobindo Pharma arm Curateq Biologics incorporates new wholly owned subsidiary in Netherlands
Aurobindo Pharma Limited, is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries. The company has 30+ manufacturing and packaging facilities that are approved by leading regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The Company’s product portfolio is spread over seven major therapeutic/product areas encompassing CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and AntiAllergic, supported by a strong R&D set-up.
